Medindia LOGIN REGISTER
Medindia

New Insights into Anti-rheumatic Drugs

by Colleen Fleiss on May 12 2018 11:18 PM

Stopping expensive biological drugs used to treat rheumatoid arthritis in patients who are in remission or who have low disease activity can save considerable costs, but it results in a small loss of quality-adjusted life years.

New Insights into Anti-rheumatic Drugs
Stopping tumor necrosis factor inhibitors in patients with stable low disease activity, on average, was associated with a cost saving of €7,133, a loss of 0.022 quality-adjusted life years, and an increase of 0.41 arthritis flares per patient per year, reveals study published in Arthritis & Rheumatology.
In the study, "The subpopulation of patients receiving biological disease modifying anti-rheumatic drugs including tumor necrosis factor inhibitors... has increased over time and accounted for up to 20% of the population of rheumatoid arthritis patients in various Western healthcare systems," the authors wrote.

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints and the surrounding tissues. It is an autoimmune disease.

Source-Eurekalert


Advertisement